IBZM- and CIT-SPECT of the dopaminergic system in parkinsonism

  • G. Tissingh
  • J. Booij
  • A. Winogrodzka
  • E. A. van Royen
  • E. Ch. Wolters
Part of the Journal of Neural Transmission. Supplementa book series (NEURAL SUPPL, volume 50)


Parkinsonism is most of the time caused by idiopathic Parkinson’s disease (IPD). Considering the differences in therapeutic response and prognosis, in vivo discrimination between IPD and “parkinsonism-plus” syndromes is important. Recently, ligands have become available for imaging the pre- and postsynaptic dopaminergic system by Single Photon Emission Computed Tomography (SPECT). Visualization of postsynaptic D2 dopamine receptors using 123I-iodobenzamide (123I-IBZM) may contribute to the differential diagnosis between IPD and “parkinsonism-plus” syndromes as IPD is a pure presynaptic disease. Imaging of the presynaptic dopamine transporters using [123I]β-CIT (2β-carbomethoxy-3β-(4-iodophenyl)tropane) may be used as a diagnostic technique. Early disease detection in subjects suspected to be at risk for developing IPD has become possible using [123I]β-CIT or other ligands for the dopamine transporter. Furthermore, with SPECT one is probably able to monitor in an objective way the efficacy of new pharmacological therapies.


Single Photon Emission Compute Tomography Multiple System Atrophy Single Photon Emission Compute Tomography Imaging Progressive Supranuclear Palsy Single Photon Emission Compute Tomography Study 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Bernheimer H, Birkmayer W, Hornykiewicz O, Jellinger K, Scitelberger F (1973) Brain Dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. J Neurol Sci 20: 415–455PubMedCrossRefGoogle Scholar
  2. Booij J, Vermeiden RJ, Tissingh G, et al (1995) Visualization of the dopamine transporter in Parkinson’s disease and multiple system atrophy: a [123–1]ß-CIT study. Acta Neurol Belg 95 [Suppl]: 35Google Scholar
  3. Brooks DJ, Ibanez V, Sawle GV, et al (1990a) Differing patterns of striatal 18F-DOPA uptake in Parkinson’s disease, multiple system atrophy and progressive supranuclear palsy. Ann Neurol 28: 547–555PubMedCrossRefGoogle Scholar
  4. Brooks DJ, Salmon EP, Mathias CJ, et al (1990b) The relationship between locomotor disability, autonomic dysfunction, and the integrity of the striatal dopaminergic system in patients with multiple system atrophy, pure autonomic failure, and Parkinson’s disease, studied with PET. Brain 113: 1539–1552PubMedCrossRefGoogle Scholar
  5. Brooks DJ (1993) Functional imaging in relation to parkinsonian syndromes. J Neurol Sci 115: 1–17PubMedCrossRefGoogle Scholar
  6. Brücke T, Podreka I, Angelberger P, et al (1991) Dopamine D2 receptor imaging with SPECT: studies in different neuropsychiatric disorders. J Cereb Blood Flow Metab 11: 220–228PubMedCrossRefGoogle Scholar
  7. Brücke T, Wenger S, Asenbaum S, et al (1993) Dopamine D2 receptor imaging and measurement with SPECT. In: Narabayashi H, Nagatsu T, Yanagisawa N, Mizuno Y (eds) Advances in Neurology, vol 60. Raven Press, New YorkGoogle Scholar
  8. Carroll FI, Scheffel U, Dannals RF, Boja JW, Kuhar MJ (1995) Development of imaging agents for the dopamine transporter. Med Res Rev 15: 419–444PubMedCrossRefGoogle Scholar
  9. Churchyard A, Donnan GA, Hughes A, et al (1993) Dopa resistance in multiple-system atrophy: loss of postsynaptic D2 receptors. Ann Neurol 34: 219–226PubMedCrossRefGoogle Scholar
  10. Fearnley JM, Lees AJ (1990) Striatonigral degeneration: a clinico-pathological study. Brain 113: 1823–1842PubMedCrossRefGoogle Scholar
  11. Harrison MB, Wiley RG, Wooten GF (1992) Changes in D2 but not D1 receptor binding in the striatum following selective lesion of striatopallidal neurons. Brain Res 590: 305–310PubMedCrossRefGoogle Scholar
  12. Hughes A, Lees AJ, Stern GM (1990) Apomorphine test to predict dopaminergic responsiveness in parkinsonian syndromes. Lancet 336: 32–34PubMedCrossRefGoogle Scholar
  13. Hughes AJ, Daniel SE, Kilford L, Lees AJ (1992) Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 55: 181–184PubMedCrossRefGoogle Scholar
  14. Innis RB, Scibyl JP, Scanley BE, et al (1993) Single photon emission computed tomographic imaging demonstrates loss of striatal dopamine transporters in Parkinson’s disease. Proc Natl Acad Sci USA 90: 11965–11969PubMedCrossRefGoogle Scholar
  15. Innis RB (1994) Single-photon emission tomography imaging of dopamine terminal innervation: a potential clinical tool in Parkinson’s disease. Eur J Nucl Med 21: 1–5PubMedCrossRefGoogle Scholar
  16. Kaufman MJ, Madras BK (1991) Severe depletion of cocaine recognition sites associated with the dopamine transporter in Parkinson’s disease striatum. Synapse 9: 43–49PubMedCrossRefGoogle Scholar
  17. Kish SJ, Shannak K, Hornykiewics O (1988) Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson’s disease. N Engl J Med 318: 876–880PubMedCrossRefGoogle Scholar
  18. Kung HF, Alavi A, Chang W, et al (1990) In vivo SPECT imaging of CNS D-2 dopamine receptors: initial studies with iodine-123-IBZM in humans. J Nucl Med 31: 573–579PubMedGoogle Scholar
  19. Lamelle M, Baldwin RM, Malison RT, et al (1993) SPECT imaging of dopamine and serotonin transporters with [123I]ß-CIT: pharmacological characterization of brain uptake in nonhuman primates. Synapse 13: 295–309CrossRefGoogle Scholar
  20. Laulumaa V, Kuikka JT, Soininen H, Bergström K, Länsimies E, Riekkinen P (1993) Imaging of D2 dopamine receptors of patients with Parkinson’s disease using single photon emission computed tomography and iodobenzamide I 123. Arch Neurol 50: 509–512PubMedCrossRefGoogle Scholar
  21. Neumeyer JL, Wang S, Millius RA, et al (1991) [123I]-2ß-carbomethoxy-3ß-(4- iodophenyl) tropane: high-affinity SPECT radiotracer of monoamine reuptake sites in brain. J Med Chem 34: 3144–3146PubMedCrossRefGoogle Scholar
  22. Neumeyer JL, Wang S, Gao Y, et al (1994) N-3-fluoroalkyl analogs of (lR)-2ß-carbomethoxy-3ß-(4-iodophenyl)-tropane (ß-CIT) radiotracers for positron emission tomography and single photon emission computed tomography imaging of dopamine transporters. J Med Chem 37: 1558–1561PubMedCrossRefGoogle Scholar
  23. Oertel WH, Gasser T, Ippisch R, Trenkwalder C, Poewe W (1989) Apomorphine test for dopaminergic responsiveness. Lancet 1: 1262–1263CrossRefGoogle Scholar
  24. Oertel WH, Schwarz J, Tatsch K, Arnold G, Gasser T, Kirsch C-M (1993) IBZM-SPECT as predictor for dopamimetic responsiveness of patients with de novo parkinsonian syndrome. In: Narabayashi H, Nagatsu T, Yanagisawa N, Mizuno Y (eds) Advances in neurology, vol 60. Raven Press, New YorkGoogle Scholar
  25. Pascual J, Berciano J, Grijalba B, Del Olmo E, Gonzalez AM, Figols J, Pazos A (1992) Dopamine D1 and D2 receptors in progressive supranuclear palsy: an autoradiographic study. Ann Neurol 32: 703–707PubMedCrossRefGoogle Scholar
  26. Quinn N (1989) Multiple system atrophy — the nature of the beast. J Neurol Neurosurg Psychiatry [spec Suppl] 78–89Google Scholar
  27. Rajput AH, Offord KP, Beard CM, Kurland LT (1984) Epidemiology of parkinsonism: incidence, classification, and mortality. Ann Neurol 16: 278–282PubMedCrossRefGoogle Scholar
  28. Rinne JO, Kuikka JT, Bergström KA, Rinne UK (1995) Striatal dopamine transporter in different disability stages of Parkinson’s disease studied with [123]ß-CIT SPECT. Parkinsonism & Related Disorders 1: 47–51CrossRefGoogle Scholar
  29. Rosenthal MS, Cullom J, Hawkins W, Moore SC, Tsui BMW, Yester M (1995) Quantitative SPECT imaging: a review and recommendations by the focus committee of the society of nuclear medicine computer and instrumentation council. J Nucl Med 36: 1489–1513PubMedGoogle Scholar
  30. Schulz JB, Klockgether T, Petersen D, et al (1994) Multiple system atrophy: natural history, MRI morphology, and dopamine receptor imaging with 123IBZM-SPECT. J Neurol Neurosurg Psychiatry 57: 1047–1056.PubMedCrossRefGoogle Scholar
  31. Schwarz J, Tatsch K, Arnold G, Gasser T, Trenkwalder C, Kirsch CM, Oertel WH (1992) 123I-Iodobenzamide-SPECT predicts dopaminergic responsiveness in patients with de novo parkinsonism. Neurology 42: 556–561PubMedCrossRefGoogle Scholar
  32. Schwarz J, Tatsch K, Arnold G, Ott M, Trenkwalder C, Kirsch CM, Oertel WH (1993) 123I-Iodobenzamide-SPECT in 83 patients with de novo parkinsonism. Neurology 43 [Suppl 6]: S17–20PubMedGoogle Scholar
  33. Scibyl JP, Marek KL, Quinlan D, et al (1995) Decreased single-photon emission computed tomographic [123I]ß-CIT striatal uptake correlates with symptom severity in Parkinson’s disease. Ann Neurol 38: 589–598CrossRefGoogle Scholar
  34. Spokes EGS, Bannister R, Oppenheimer DR (1979) Multiple system atrophy with autonomic failure. Clinical, histological, and neurochemical observations on four cases. J Neurol Sci 43: 59–82PubMedCrossRefGoogle Scholar
  35. Tatsch K, Schwarz J, Oertel WH, Kirsch C-M (1991) SPECT imaging of dopamine D2 receptors with 123I-IBZM: initial experience in controls and patients with Parkinson’s syndrome and Wilson’s disease. Nucl Med Commun 12: 699–707PubMedCrossRefGoogle Scholar
  36. Van Royen E, Verhoeff NFLG, Speelman JD, Wolters EC, Kuiper MA, Janssen AGM (1993) Multiple system atrophy and progressive supranuclear palsy. Diminished striatal D2 dopamine receptor activity demonstrated by 123I-IBZM single photon emission computed tomography. Arch Neurol 50: 513–516PubMedCrossRefGoogle Scholar
  37. Verhoeff NPLG, Buell U, Costa DC, et al (1992) Basics and recommendations for brain SPECT. Nuklearmedizin 31: 114–131Google Scholar
  38. Vermeulen RJ, Wolters ECh, Tissingh G, et al (1995) Evaluation of [123I]ß-CIT binding with SPECT in controls, early and late Parkinson’s disease. Nucl Med Biol 22: 985–991PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Wien 1997

Authors and Affiliations

  • G. Tissingh
    • 1
  • J. Booij
    • 2
  • A. Winogrodzka
    • 1
  • E. A. van Royen
    • 2
  • E. Ch. Wolters
    • 1
  1. 1.Graduate School Neurosciences Amsterdam, Department of NeurologyAcademisch Ziekenhuis VU AmsterdamAmsterdamThe Netherlands
  2. 2.Department of Nuclear MedicineAcademic Medical Center University of AmsterdamAmsterdamThe Netherlands

Personalised recommendations